Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ILK | Q13418 | 1/20 | 0.39 |
| ▸ | MYC | P01106 | 2/20 | 0.37 |
| ▸ | F2RL3 | Q96RI0 | 3/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.35 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.34 |
| ▸ | AHR | P35869 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18293350 | 1.00 | ILK (0.39) | ILKMYCF2RL3DYRK1AMKNK1 | |
| SCHEMBL20248834 | 0.90 | L3MBTL1 (0.40) | ILKMYCDYRK1AMKNK1ADORA1 | |
| SCHEMBL30407882 | 0.90 | ILK (0.42) | ILKMYCDYRK1AADORA1KDM4E | |
| SCHEMBL18293093 | 0.90 | ILK (0.42) | ILKMYCDYRK1AADORA1KDM4E | |
| SCHEMBL18293284 | 0.90 | MYC (0.37) | ILKMYCDYRK1AMKNK1ADORA1 | |
| SCHEMBL18293209 | 0.90 | MYC (0.37) | ILKMYCDYRK1AMKNK1ADORA1 | |
| SCHEMBL30407403 | 0.90 | MYC (0.37) | ILKMYCDYRK1AMKNK1ADORA1 | |
| SCHEMBL30408451 | 0.90 | MYC (0.37) | ILKMYCDYRK1AMKNK1ADORA1 | |
| SCHEMBL18286053 | 0.88 | ILK (0.42) | ILKMYCF2RL3DYRK1AAHR | |
| SCHEMBL18285929 | 0.88 | APEX1 (0.43) | MYCKDM4EMAPTLMNARXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230144106-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | SYROS PHARMACEUTICALS INC (US) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230144106-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | MYC, MYCBP, MYCBP2 | ILK 1671/4885MYC 1/4885F2RL3 2304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.